Allyson Perry

Bisphosphonates and denosumab are bone-modifying agents that prevent or delay cancer-induced bone disease and skeletal-related events by inhibiting bone resorption.

Checkpoint inhibition has demonstrated efficacy for the treatment of melanoma in several clinical trials. However, biomarkers to predict safety and efficacy of immunotherapies in individual melanoma patients are lacking.